Cathepsin A knockdown decreases the proliferation and invasion of A549 lung adenocarcinoma cells

Hu,Bo; Zhu,Xike; Lu,Jibin

doi:10.3892/mmr.2020.11068

Cathepsin A knockdown decreases the proliferation and invasion of A549 lung adenocarcinoma cells

Authors:
- Bo Hu
- Xike Zhu
- Jibin Lu
View Affiliations

Affiliations: Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Research Center, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: April 10, 2020 https://doi.org/10.3892/mmr.2020.11068
Pages: 2553-2559
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cathepsin A (CTSA) is a lysosomal protease that is abnormally expressed in various types of cancer; however, the function of CTSA in lung adenocarcinoma (LUAD) is unknown. The aim of the present study was to investigate the role of CTSA during LUAD development in vitro. The Cancer Genome Atlas (TCGA) database was used to analyze the expression of CTSA mRNA in LUAD tissues. CTSA was significantly upregulated in LUAD tissues compared with normal lung tissues. To explore the effect of CTSA on LUAD in vitro, LUAD A549 cells were transfected with CTSA small interfering RNA and the hallmarks of tumorigenesis were investigated using cell proliferation, cell cycle, wound healing, invasion and western blot assays. Following CTSA knockdown, proliferation of LUAD cells was decreased and an increased proportion of LUAD cells were arrested at the G0/G1 phase, with altered expression of critical cell cycle and proliferative marker proteins, including p53, p21 and proliferating cell nuclear antigen. Moreover, CTSA knockdown decreased the migration and invasion of A549 cells, as determined by wound healing, invasion, and western blotting assays. The expression levels of key proteins involved in epithelial‑mesenchymal transition were analyzed by western blotting. CTSA knockdown enhanced the expression of E‑cadherin, but decreased the expression of N‑cadherin and β‑catenin in A549 cells. To the best of our knowledge, the present study suggested for the first time it has been identified that CTSA may serve as a tumor promoter in LUAD, enhancing the malignant progression of LUAD cells by promoting cell proliferation, migration and invasion. The results suggested that CTSA may serve as a novel therapeutic target for LUAD.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
2	Cancer Genome Atlas Research Network, . Comprehensive molecular profiling of lung adenocarcinoma. Nature. 511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
3	Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW and Groen HJ: Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 26:902–907. 2015. View Article : Google Scholar : PubMed/NCBI
4	Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
5	Pan L, Li Y, Jia L, Qin Y, Qi G, Cheng J, Qi Y, Li H and Du J: Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One. 7:e353152012. View Article : Google Scholar : PubMed/NCBI
6	Dennemärker J, Lohmüller T, Müller S, Aguilar SV, Tobin DJ, Peters C and Reinheckel T: Impaired turnover of autophagolysosomes in cathepsin L deficiency. Biol Chem. 391:913–922. 2010. View Article : Google Scholar : PubMed/NCBI
7	Drake MT, Clarke BL, Oursler MJ and Khosla S: Cathepsin K inhibitors for osteoporosis: Biology, potential clinical utility, and lessons learned. Endocr Rev. 38:325–350. 2017. View Article : Google Scholar : PubMed/NCBI
8	Olson OC and Joyce JA: Cysteine cathepsin proteases: Regulators of cancer progression and therapeutic response. Nat Rev Cancer. 15:712–729. 2015. View Article : Google Scholar : PubMed/NCBI
9	Akkari L, Gocheva V, Quick ML, Kester JC, Spencer AK, Garfall AL, Bowman RL and Joyce JA: Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes Dev. 30:220–232. 2016. View Article : Google Scholar : PubMed/NCBI
10	Kolli N and Garman SC: Proteolytic activation of human cathepsin A. J Biol Chem. 289:11592–11600. 2014. View Article : Google Scholar : PubMed/NCBI
11	You Y, Li WZ, Zhang S, Hu B, Li YX, Li HD, Tang HH, Li QW, Guan YY, Liu LX, et al: SNX10 mediates alcohol-induced liver injury and steatosis by regulating the activation of chaperone-mediated autophagy. J Hepatol. 69:129–141. 2018. View Article : Google Scholar : PubMed/NCBI
12	Verbovšek U, Van Noorden CJ and Lah TT: Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. Semin Cancer Biol. 35:71–84. 2015. View Article : Google Scholar : PubMed/NCBI
13	Sudhan DR and Siemann DW: Cathepsin L targeting in cancer treatment. Pharmacol Ther. 155:105–116. 2015. View Article : Google Scholar : PubMed/NCBI
14	Yuan L, Sheng L, He W, Zou C, Hu B, Liu J, Ge W, Liu Y, Wang J and Ma E: Discovery of novel cathepsin inhibitors with potent anti-metastatic effects in breast cancer cells. Bioorg Chem. 81:672–680. 2018. View Article : Google Scholar : PubMed/NCBI
15	Ni S, Weng W, Xu M, Wang Q, Tan C, Sun H, Wang L, Huang D, Du X and Sheng W: miR-106b-5p inhibits the invasion and metastasis of colorectal cancer by targeting CTSA. Onco Targets Ther. 11:3835–3845. 2018. View Article : Google Scholar : PubMed/NCBI
16	Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR and Rakha EA: The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. Histopathology. 74:1025–1035. 2019. View Article : Google Scholar : PubMed/NCBI
17	Kozlowski L, Wojtukiewicz MZ and Ostrowska H: Cathepsin A activity in primary and metastatic human melanocytic tumors. Arch Dermatol Res. 292:68–71. 2000. View Article : Google Scholar : PubMed/NCBI
18	Cancer Genome Atlas Research Network, . Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
19	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
20	Hung JJ, Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC, Chou TY and Hsu WH: Predictive value of the international association for the study of lung cancer/American thoracic society/European respiratory society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 32:2357–2364. 2014. View Article : Google Scholar : PubMed/NCBI
21	Reinheckel T, Hagemann S, Dollwet-Mack S, Martinez E, Lohmuller T, Zlatkovic G, Tobin DJ, Maas-Szabowski N and Peters C: The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci. 118:3387–3395. 2005. View Article : Google Scholar : PubMed/NCBI
22	Platt MO and Shockey WA: Endothelial cells and cathepsins: Biochemical and biomechanical regulation. Biochimie. 122:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
23	Brojatsch J, Lima H Jr, Palliser D, Jacobson LS, Muehlbauer SM, Furtado R, Goldman DL, Lisanti MP and Chandran K: Distinct cathepsins control necrotic cell death mediated by pyroptosis inducers and lysosome-destabilizing agents. Cell Cycle. 14:964–972. 2015. View Article : Google Scholar : PubMed/NCBI
24	Wang L, Zhao Y, Xiong Y, Wang W, Fei Y, Tan C and Liang Z: K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L/CUX1 pathway. Exp Cell Res. 362:424–435. 2018. View Article : Google Scholar : PubMed/NCBI
25	Willumsen N, Bager CL, Leeming DJ, Bay-Jensen AC and Karsdal MA: Nidogen-1 degraded by cathepsin S can be quantified in serum and is associated with non-small cell lung cancer. Neoplasia. 19:271–278. 2017. View Article : Google Scholar : PubMed/NCBI
26	Tsai JY, Lee MJ, Dah-Tsyr Chang M and Huang H: The effect of catalase on migration and invasion of lung cancer cells by regulating the activities of cathepsin S, L, and K. Exp Cell Res. 323:28–40. 2014. View Article : Google Scholar : PubMed/NCBI
27	Jechorek D, Votapek J, Meyer F, Kandulski A, Roessner A and Franke S: Characterization of cathepsin X in colorectal cancer development and progression. Pathol Res Pract. 210:822–829. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhang W, Wang S, Wang Q, Yang Z, Pan Z and Li L: Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer. Oncol Rep. 31:1334–1342. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yamashita K, Iwatake M, Okamoto K, Yamada SI, Umeda M and Tsukuba T: Cathepsin K modulates invasion, migration and adhesion of oral squamous cell carcinomas in vitro. Oral Dis. 23:518–525. 2017. View Article : Google Scholar : PubMed/NCBI
30	Aggarwal N and Sloane BF: Cathepsin B: Multiple roles in cancer. Proteomics Clin Appl. 8:427–437. 2014. View Article : Google Scholar : PubMed/NCBI
31	Schweiger A, Staib A, Werle B, Krasovec M, Lah TT, Ebert W, Turk V and Kos J: Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: Relation to prognosis and cigarette smoking. Br J Cancer. 82:782–788. 2000. View Article : Google Scholar : PubMed/NCBI
32	Ruan J, Zheng H, Fu W, Zhao P, Su N and Luo R: Increased expression of cathepsin L: A novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients. PLoS One. 9:e1121362014. View Article : Google Scholar : PubMed/NCBI
33	Han ML, Zhao YF, Tan CH, Xiong YJ, Wang WJ, Wu F, Fei Y, Wang L and Liang ZQ: Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin. 37:1606–1622. 2016. View Article : Google Scholar : PubMed/NCBI
34	Turk V, Turk B, Guncar G, Turk D and Kos J: Lysosomal cathepsins: Structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul. 42:285–303. 2002. View Article : Google Scholar : PubMed/NCBI
35	Pastushenko I and Blanpain C: EMT Transition states during tumor progression and metastasis. Trends Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
36	Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437. 2009. View Article : Google Scholar : PubMed/NCBI
37	Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D and Joyce JA: Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20:543–556. 2006. View Article : Google Scholar : PubMed/NCBI
38	Kallunki T, Olsen OD and Jäättelä M: Cancer-associated lysosomal changes: Friends or foes? Oncogene. 32:1995–2004. 2013. View Article : Google Scholar : PubMed/NCBI
39	Harris SL and Levine AJ: The p53 pathway: Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005. View Article : Google Scholar : PubMed/NCBI